Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847395 | 1.00 | FAAH (0.58) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL30304049 | 0.85 | FAAH (0.56) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL11370888 | 0.84 | MAPT (0.47) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL25980986 | 0.84 | FAAH (0.43) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL6906595 | 0.82 | FAAH (0.65) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL8506453 | 0.82 | FAAH (0.75) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL9986402 | 0.82 | FAAH (0.65) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL9447664 | 0.82 | FAAH (0.65) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL13126847 | 0.82 | FAAH (0.65) | FAAHCNR1CNR2ALDH1A1MAPT | |
| SCHEMBL6339017 | 0.82 | FAAH (0.65) | FAAHCNR1CNR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258321-B2 | Beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | LBR, CYP8B1, GLB1 | FAAH 442/4885CNR1 321/4885CNR2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.